Evidence map›Paper›PMID 36358606›Full record

ArticleCancers2022

Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study.

David J Carpenter, Brahma Natarajan, Muzamil Arshad, Divya Natesan, Olivia Schultz, Michael J Moravan, Charlotte Read, Kyle J Lafata, Will Giles, Peter Fecci and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

David J CarpenterDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Brahma NatarajanDepartment of Medicine, University of Carolina Chapel Hill, Chapel Hill, NC 27599, USA.
Muzamil ArshadDepartment of Radiation Oncology, University of Chicago, Chicago, IL 60637, USA.
Divya NatesanDepartment of Radiation Oncology, University of Carolina Chapel Hill, Chapel Hill, NC 27599, USA.
Olivia SchultzDepartment of Radiation Oncology, University of Chicago, Chicago, IL 60637, USA.
Michael J MoravanRadiation Oncology Clinical Service, Veterans Affairs St. Louis Health Care System, St. Louis, MO 63110, USA.
Charlotte ReadDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-2073-6678
Kyle J LafataDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Will GilesDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Peter FecciDepartment of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-2912-8695
Trey C MullikinDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Zachary J ReitmanDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
John P KirkpatrickDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Scott R FloydDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Steven J ChmuraDepartment of Radiation Oncology, University of Chicago, Chicago, IL 60637, USA.
Julian C HongDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA.
Joseph K SalamaDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

Funding

Duke Radiation Oncology and Radiology Stimulating Access to Research in ResidencyR38CA245204 · NCI · DUKE UNIVERSITY · PI FLOYD, SCOTT R · 2020 to 2023
$1.4M
NCI NIH HHS R38 CA245204NIH HHS R38CA24520401
6 · The paper itself

Abstract

Stereotactic radiosurgery (SRS) is a standard of care for many patients with brain metastases. To optimize post-SRS surveillance, this study aimed to validate a previously published nomogram predicting post-SRS intracranial progression (IP). We identified consecutive patients completing an initial course of SRS across two institutions between July 2017 and December 2020. Patients were classified as low- or high-risk for post-SRS IP per a previously published nomogram. Overall survival (OS) and freedom from IP (FFIP) were assessed via the Kaplan−Meier method. Assessment of parameters impacting FFIP was performed with univariable and multivariable Cox proportional hazard models. Among 890 patients, median follow-up was 9.8 months (95% CI 9.1−11.2 months). In total, 47% had NSCLC primary tumors, and 47% had oligometastatic disease (defined as ≤5 metastastic foci) at the time of SRS. Per the IP nomogram, 53% of patients were deemed high-risk. For low- and high-risk patients, median FFIP was 13.9 months (95% CI 11.1−17.1 months) and 7.6 months (95% CI 6.4−9.3 months), respectively, and FFIP was superior in low-risk patients (p < 0.0001). This large multisite BM cohort supports the use of an IP nomogram as a quick and simple means of stratifying patients into low- and high-risk groups for post-SRS IP.

Indexed as

brain metastasesintracranial progressionstereotactic radiosurgery

Identifiers

PMID36358606
PMCPMC9657742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.